Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Tuberculosis

Free Subscription Articles published in Clin Infect Dis Retrieve available abstracts of 200 articles: HTML format

Single Articles

September 2026
1. MCKENNA L, Frick M, Alarcon-Guizado VA, Davies GR, et al
   When are Uncontrolled Trials in TB Scientifically and Ethically Justified: Borrowing Wisdom From Early AIDS Clinical Trials.
   Clin Infect Dis. 2026;83:e399-e403.
   PubMed     Abstract available
   
   
   August 2026
2. ZAZUETA OE, Becerra MC, Galea JT, Calderon RI, et al
   The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression.
   Clin Infect Dis. 2026 Aug 17:ciag483. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. 
   Correction to: The TSwaY Study Network, Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries.
   Clin Infect Dis. 2026 Aug 4:ciag455. doi: 10.1093.
   PubMed    
   
   
   July 2026
4. 
   Correction to: Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa.
   Clin Infect Dis. 2026 Jul 25:ciag448. doi: 10.1093.
   PubMed    
   
   
   
5. SINHA P, Goffin BD, Karoly M, Kumar N, et al
   Incorporating ambient air pollution as a risk factor for tuberculosis mortality in Delhi, India.
   Clin Infect Dis. 2026 Jul 15:ciag424. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. CROSS GB, Walker HN, Hasan T, Berry C, et al
   We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness.
   Clin Infect Dis. 2026;82:e1326-e1332.
   PubMed     Abstract available
   
   
   
7. SHEN E, Algozhin Y, Trevisi L, LaHood A, et al
   Low Post-Treatment Recurrence After a Shortened All-oral Regimen for Pulmonary Rifampicin- or Multidrug-Resistant Tuberculosis in Individuals without Prior Second-Line Drug Exposure in Kazakhstan.
   Clin Infect Dis. 2026 Jul 1:ciag391. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2026
8. MOHAN G, Hanrahan CF, Martinez-Amezcua P, Hoffmann CJ, et al
   Multidimensional Poverty and Implementation Reach of Household Contact Tracing for Tuberculosis in South Africa: Analysis of a Randomized Trial.
   Clin Infect Dis. 2026 Jun 17:ciag321. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. ROMO M, LaHood A, Mitnick CD, Rich ML, et al
   Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulation.
   Clin Infect Dis. 2026 Jun 12:ciag361. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. SIDDIQI OK, Jahn B, Rochau U, Walukaga S, et al
    Cost-effectiveness Analysis of Xpert MTB/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis.
    Clin Infect Dis. 2026 Jun 9:ciag348. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2026
11. MA Z, Yu X, Yu Y, Wang Y, et al
    Near-point-of-care diagnosis of tuberculosis with LyocartE MTB Assay: a multicentre diagnostic accuracy study.
    Clin Infect Dis. 2026 May 29:ciag342. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. VUYYURU SK, Singh U, Das P, Basant S, et al
    Association of Mycobacterium avium paratuberculosis With Crohn's Disease: A Large Multicenter Study From a Tuberculosis-Endemic Region.
    Clin Infect Dis. 2026;82:841-847.
    PubMed     Abstract available
    
    
    
13. HUANG CC, Tan Q, Becerra MC, Calderon R, et al
    Impact of Diabetes Mellitus in Tuberculosis (TB) Patients on TB Transmission.
    Clin Infect Dis. 2026;82:829-840.
    PubMed     Abstract available
    
    
    
14. CHANG VWL, Li Q, Barnes D, Byrne AL, et al
    Three months of weekly rifapentine and isoniazid versus four months of rifampicin for tuberculosis infection: a randomised controlled trial.
    Clin Infect Dis. 2026 May 15:ciag306. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. BARRY SE
    Efficacy Is Not Enough: Delivering Tuberculosis Preventive Therapy in the Real World.
    Clin Infect Dis. 2026 May 12:ciag307. doi: 10.1093.
    PubMed    
    
    
    April 2026
16. BHAVARAJU R, Andrade B, Siminski S, Kim S, et al
    A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis.
    Clin Infect Dis. 2026;82.
    PubMed     Abstract available
    
    
    
17. GUPTE AN, Boisson-Walsh A, Huaman MA, Bhavaraju R, et al
    Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review.
    Clin Infect Dis. 2026;82.
    PubMed     Abstract available
    
    
    
18. ARAUJO-PEREIRA M, Bhavaraju R, Hatherill M, Gupta A, et al
    From Exposure to Disease: Predicting Tuberculosis Progression.
    Clin Infect Dis. 2026;82.
    PubMed     Abstract available
    
    
    
19. DUARTE BB, Ellner J, Wright AD, Hatherill M, et al
    Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications.
    Clin Infect Dis. 2026;82.
    PubMed     Abstract available
    
    
    
20. ZHAN S, Liu W, Yang L, Chen Z, et al
    Fixed-Dose Rifapentine-Isoniazid (1HP) for Tuberculosis Preventive Treatment in Chinese Adults: A Prospective Real-World Safety and Pharmacokinetic Study.
    Clin Infect Dis. 2026 Apr 13:ciag247. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2026
21. YANG Y
    When IS900 Positivity is not the Tie-Breaker: Interpreting Mycobacterium avium Subspecies paratuberculosis Signals Across Crohn's Disease and Intestinal Tuberculosis in a Tuberculosis-Endemic Setting.
    Clin Infect Dis. 2026 Mar 27:ciag127. doi: 10.1093.
    PubMed    
    
    
    
22. VISEK C, Dalmat RR, Nalutaaya A, Erisa KC, et al
    Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings.
    Clin Infect Dis. 2026 Mar 20:ciag019. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. KUMAR D SS, Somarkutty N, Prasad D JH, Gautam P, et al
    Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study.
    Clin Infect Dis. 2026 Mar 20:ciaf573. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. VARGAS DA, Fuertes-Bucheli JF, Sanchez-Hidalgo A, Palomares Velosa J, et al
    Diagnostic Accuracy of Molecular Testing on Saliva and Oral Swabs for Pulmonary Tuberculosis.
    Clin Infect Dis. 2026 Mar 12:ciag055. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. KOSENKO M, Davtian L, Iakovleva E, Ashurov M, et al
    Shorter Antitubercular Regimens Versus 9 Months of Isoniazid for Latent Tuberculosis in Children: A Systematic Review and Meta-Analysis.
    Clin Infect Dis. 2026 Mar 10:ciag073. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. MOE CA, Luswata RK, Barrameda AJ, Le H, et al
    Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries.
    Clin Infect Dis. 2026 Mar 10:ciag077. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. YANG E, Van Brantegem P, Peloquin CA, Brooks MB, et al
    Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis.
    Clin Infect Dis. 2026 Mar 6:ciag141. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2026
28. APRIANI L, Sidhu H, Korobitsyn A, Ismail N, et al
    Diagnostic Performance of New Commercial IGRAs for Mycobacterium tuberculosis Infection: An updated Systematic Review and Meta-analysis.
    Clin Infect Dis. 2026 Feb 25:ciag102. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. CROWDER R, Thangakunam B, Andama A, Christopher DJ, et al
    Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein.
    Clin Infect Dis. 2026;82:e239-e247.
    PubMed     Abstract available
    
    
    
30. CHEN R, Shen Y, Liu H, Wang M, et al
    Intrathecal Isoniazid and Dexamethasone Therapy May Improve Outcomes in Patients with Tuberculous Meningitis: A Two-Center Retrospective Cohort Study.
    Clin Infect Dis. 2026 Feb 18:ciag106. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. CAMPBELL JI, Brooks MB, Dankovchik J, Giebultowicz S, et al
    Uncovering household tuberculosis infection testing and care patterns using a novel bioinformatics linkage strategy.
    Clin Infect Dis. 2026 Feb 11:ciag079. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. KUHLIN J, Stadler JAM, Grint DJ, Court R, et al
    Treatment adherence with an oral nine-month regimen for rifampicin-resistant tuberculosis in South Africa.
    Clin Infect Dis. 2026 Feb 9:ciag069. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. WANG Y, Li R, Cai L, Jin L, et al
    Accuracy of rapid quantitative PCR on tongue swabs for pulmonary tuberculosis in sputum-scarce patients: a prospective multicentre diagnostic study.
    Clin Infect Dis. 2026 Feb 9:ciag071. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. GRINT DJ, Dhillon J, Butcher PD, Adams J, et al
    Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification.
    Clin Infect Dis. 2026;82:e126-e134.
    PubMed     Abstract available
    
    
    
35. DE NOOY A, Omar SV, Ockhuisen T, Zwerling A, et al
    Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa.
    Clin Infect Dis. 2026;82:e119-e125.
    PubMed     Abstract available
    
    
    
36. SOLOVYEVA AV, Volchenkov GV, Ponomarenko OI, Kuznezova TA, et al
    Implementing a Program of Comprehensive Tuberculosis Preventive Treatment: Safety, Effectiveness, and Acceptability of Moxifloxacin or Bedaquiline Use for Contacts Exposed to Drug-Resistant Strains.
    Clin Infect Dis. 2026 Feb 3:ciaf701. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2026
37. MANZOOR F, Rhee C, Baker MA, Klompas M, et al
    Mycobacterium tuberculosis Transmission in Healthcare Settings: A Systematic Review of Frequency, Risk Factors, and Exposure Conditions.
    Clin Infect Dis. 2026 Jan 30:ciag053. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. LOVEDAY M, Clarence E, Hlangu S, Singh N, et al
    Pregnant women with MDR/RR-TB and the all-oral 6-month regimen: experiences from a patient series in South Africa.
    Clin Infect Dis. 2026 Jan 22:ciag032. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. STARKE S, Thomas K, Jasuja S, Lubelchek R, et al
    Short-Course Tuberculosis Preventive Therapy in a High Migration Setting: Early Experience With 1HP in Cook County, Illinois.
    Clin Infect Dis. 2026 Jan 21:ciaf723. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. SWEETSER B, Nguyen H, Dang H, Katumba D, et al
    Evaluating the Cepheid Xpert TB/LTBI research-use-only assay for detection of active and latent Mycobacterium tuberculosis infection.
    Clin Infect Dis. 2026 Jan 21:ciag005. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. NIWARD K, Braian C, Svardhagen G, Augustinsson D, et al
    Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine-An Approach for Clinical Management.
    Clin Infect Dis. 2026 Jan 15:ciaf663. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. NALUGWA T, Shah KM, Marcelo D, Nakawunde R, et al
    Predicted Preferences for Tuberculosis Point-of-Care Tests among Tuberculosis-Affected Individuals in Five High Burden Countries.
    Clin Infect Dis. 2026 Jan 14:ciag022. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. 
    Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa.
    Clin Infect Dis. 2026 Jan 9:ciaf711. doi: 10.1093.
    PubMed    
    
    
    December 2025
44. OSUALA EC, Nkuhairwe IN, Letsoalo MP, Naidoo K, et al
    Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and Rifampicin.
    Clin Infect Dis. 2025 Dec 30:ciaf732. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. SALAZAR-AUSTIN N, Cohn S, Nonyane BAS, Mulder C, et al
    Effectiveness of a Home-based Approach to Child Contact Investigation and Tuberculosis Preventive Treatment Management by Community Health Workers in Ethiopia: A Pragmatic Cluster-randomized Trial.
    Clin Infect Dis. 2025;81:e385-e392.
    PubMed     Abstract available
    
    
    
46. MBULI C, Jean Bosco TF, Nsamenang R, Nestor B, et al
    Diagnostic performance of the Pluslife MiniDock MTB and Molbio MTB Ultima assays to detect tuberculosis from tongue and sputum swabs among outpatients and in active case finding in Cameroon.
    Clin Infect Dis. 2025 Dec 23:ciaf709. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. MARINO AM, Arua E, de Vos L, Fiphaza K, et al
    Hidden in Success: Gendered Patterns of Suboptimal Care Engagement Among TB Patients Who "Successfully" Completed Treatment in South Africa.
    Clin Infect Dis. 2025 Dec 19:ciaf714. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. CALDERIN JM, Resendiz-Galvan JE, Abdelgawad N, Davis A, et al
    Pharmacokinetics of Dexamethasone in Tuberculous Meningitis.
    Clin Infect Dis. 2025 Dec 18:ciaf642. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. MCCREESH N, MacPherson P, Bampi JVB, Engel N, et al
    Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State.
    Clin Infect Dis. 2025 Dec 10:ciaf611. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. DALE KD
    Why we should move away - not towards - symptom-based terminology and policy in tuberculosis.
    Clin Infect Dis. 2025 Dec 5:ciaf667. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2025
51. NGUYEN HT, Vo LNQ, Codlin AJ, Forse R, et al
    Diagnostic Accuracy of the STANDARD F TB-Feron FIA Assay for Tuberculosis Infection in Vietnam: A Cross-Sectional Study.
    Clin Infect Dis. 2025 Nov 26:ciaf561. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. MURRILL MT, Velasquez GE, Szumowski JD, Phillips A, et al
    Tuberculosis infection screening recommendations for targeted immunotherapies: comparison of U.S. prescribing information, clinical resources and quality measures.
    Clin Infect Dis. 2025 Nov 19:ciaf628. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2025
53. LOVEDAY M, Hughes J, Mchunu N, Yende-Zuma N, et al
    Maternal, pregnancy and infant outcomes in women treated for multidrug/rifampicin-resistant tuberculosis with novel and repurposed drugs in KwaZulu-Natal, South Africa.
    Clin Infect Dis. 2025 Oct 29:ciaf593. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. WIJK M, Denti P, Gausi K, Myers B, et al
    Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment.
    Clin Infect Dis. 2025 Oct 24:ciaf586. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. MINGCHAY P, Kawkitinarong K, Torvorapanit P, Ohata PJ, et al
    Effectiveness of Nebulized Bronchodilator - Enhanced Sputum Induction in Thai Patients with Presumed Pulmonary Tuberculosis; A Randomized Controlled Trial; (NeB-TB Trial).
    Clin Infect Dis. 2025 Oct 23:ciaf580. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. MULENGA H, Shenje J, Mendelsohn SC, Luabeya AKK, et al
    Asymptomatic Tuberculosis in Children with Household Exposure to Mycobacterium tuberculosis.
    Clin Infect Dis. 2025 Oct 15:ciaf562. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. CHEN SC, Lee YT
    Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies.
    Clin Infect Dis. 2025 Oct 3:ciaf559. doi: 10.1093.
    PubMed    
    
    
    September 2025
58. RUIZ-TAGLE C, Seguel R, Villarroel L, Bernales M, et al
    Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial.
    Clin Infect Dis. 2025 Sep 26:ciaf526. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. CHEN SC, Chen CC
    Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases.
    Clin Infect Dis. 2025 Sep 25:ciaf536. doi: 10.1093.
    PubMed    
    
    
    
60. BROOKS MB, Lecca L, Becerra MC, Calderon RI, et al
    The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study.
    Clin Infect Dis. 2025 Sep 24:ciaf490. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. PEREZ-RECIO S, Grijota-Camino MD, Guardiola J, Juanola X, et al
    Prevention of Tuberculosis in Patients Treated With Biological Therapies: Twenty Years' Experience in a Specialised Tuberculosis Clinic in a Low-prevalence Country.
    Clin Infect Dis. 2025 Sep 5:ciaf491. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. ARRIAGA MB, Amorim G, Figueiredo MC, Staats C, et al
    Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts.
    Clin Infect Dis. 2025 Sep 3:ciaf475. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
63. LAW S, Fulcher I, Ashraf S, Bastard M, et al
    Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling.
    Clin Infect Dis. 2025 Aug 22:ciaf467. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. POORE H, Wambi P, Nkereuwem E, Nakafeero J, et al
    The three-gene Xpert Host Response signature for pediatric tuberculosis screening: A prospective diagnostic accuracy study.
    Clin Infect Dis. 2025 Aug 21:ciaf445. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. SINHA P, Bhargava M, Dauphinais MR, Carwile ME, et al
    In-kind Nutritional Supplementation for Persons With Drug-susceptible Tuberculosis and Their Household Contacts Would be Cost-effective for Reducing Tuberculosis Incidence and Mortality in Jharkhand, India: A Modeling Study.
    Clin Infect Dis. 2025 Aug 20:ciaf400. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. BISIMWA BC, Kiselinova M, Cuella I, Rigouts L, et al
    Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting.
    Clin Infect Dis. 2025 Aug 12:ciaf451. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. CHURCHYARD GJ, Swindells S, Gupta A, Shah NS, et al
    Preventing multidrug resistant tuberculosis: the dawn of a new era.
    Clin Infect Dis. 2025 Aug 7:ciaf426. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. CHELI S, Torre A, Schiuma M, Montrasio C, et al
    NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study.
    Clin Infect Dis. 2025;81:145-152.
    PubMed     Abstract available
    
    
    July 2025
69. MURRAY MB, Madden AE, Ofori SK
    Harmonization of Study Design and Reporting for Chronic Pulmonary Aspergillosis in Tuberculosis Patients.
    Clin Infect Dis. 2025 Jul 30:ciaf309. doi: 10.1093.
    PubMed    
    
    
    
70. BEZUIDENHOUT C, Long L, Nichols B, Meyer-Rath G, et al
    Sputum and tongue swab molecular testing for the in-home diagnosis of tuberculosis in unselected household contacts: a cost and cost-effectiveness analysis.
    Clin Infect Dis. 2025 Jul 24:ciaf389. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. LIU W, He T, Zhan S, Qin H, et al
    Safety, feasibility and rifapentine plasma concentration in Chinese children with 1 month of daily rifapentine plus isoniazid for tuberculosis infection.
    Clin Infect Dis. 2025 Jul 21:ciaf404. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. ROCKMAN L, Abdulgader SM, Minnies S, Palmer Z, et al
    Oral washes and tongue swabs for Xpert MTB/RIF Ultra-based tuberculosis diagnosis in people with and without the ability to make sputum.
    Clin Infect Dis. 2025 Jul 18:ciaf397. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. ANDREWS JR, Kendall EA, Cattamanchi A, Denkinger CM, et al
    Projecting the impact and costs of near point-of-care tuberculosis screening assays in community-based active case finding.
    Clin Infect Dis. 2025 Jul 17:ciaf395. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. MACLEAN EL, Pham YN, Pham CD, Nguyen BC, et al
    Long-term outcomes among people with multi-drug resistant tuberculosis in Vietnam: a prospective cohort study.
    Clin Infect Dis. 2025 Jul 9:ciaf363. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. LI Y, Zhang Y, Song L, Cai C, et al
    A Short, All-Oral Regimen for Pre-Extensively Drug-Resistant Tuberculosis: A Multicenter Open-label Single-arm Study.
    Clin Infect Dis. 2025 Jul 8:ciaf351. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. COX SR, Moe AH, Gupte AN, Kadam A, et al
    A point-of-care prediction tool for recurrent tuberculosis.
    Clin Infect Dis. 2025 Jul 8:ciaf353. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
77. TUGUME L, Cresswell FV, Engen NW, Tukundane A, et al
    Prognostic Value of C-Reactive Protein in Adults With Tuberculous Meningitis: A Prospective Cohort Study.
    Clin Infect Dis. 2025 Jun 24:ciaf261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. LU X, Jiang Y, Zhang R, Zhang Y, et al
    Epidemiologic and Bacterial Factors Facilitating Long-Term Transmission of Multidrug-Resistant Tuberculosis in Shanghai, China.
    Clin Infect Dis. 2025 Jun 18:ciaf313. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. AGARWAL R, Nyendak M, Chava N, Allam RR, et al
    Long-term protection from TB preventive treatment among people with HIV in a high-burden tuberculosis setting: an observational cohort study from India.
    Clin Infect Dis. 2025 Jun 16:ciaf322. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. JAGANATH D, Nabeta P, Nicol MP, Castro R, et al
    Stool processing methods for Xpert Ultra testing in childhood tuberculosis: A prospective, multi-country accuracy study.
    Clin Infect Dis. 2025 Jun 3:ciaf289. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. DE JAGER V, Mockeliunas L, You H, Simonsson USH, et al
    A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination with Meropenem plus Amoxicillin/Clavulanate Among Adults with Rifampicin-Resistant Pulmonary Tuberculosis.
    Clin Infect Dis. 2025 Jun 2:ciaf276. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
82. PURCHASE SE, Brigden J, Seddon JA, Martinson NA, et al
    Risk of tuberculosis infection in young children exposed to multidrug-resistant tuberculosis in the TB-CHAMP multi-site randomised controlled trial.
    Clin Infect Dis. 2025 May 29:ciaf284. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. BONGOMIN F, Denning DW
    Pulmonary Tuberculosis Associated Chronic Pulmonary Aspergillosis: Urgent Need to Standardize Reporting of Prevalence Studies.
    Clin Infect Dis. 2025 May 28:ciaf279. doi: 10.1093.
    PubMed    
    
    
    
84. 
    Correction to: Serial Mass Screening for Tuberculosis Among Incarcerated Persons in Brazil.
    Clin Infect Dis. 2025 May 21:ciaf223. doi: 10.1093.
    PubMed    
    
    
    
85. REGAN JJ, Wang Z, Phares CR
    The Effect of Live-Virus Vaccines on Tests for Tuberculosis Infection During the US Immigration Medical Examination: Are Vaccines Causing False-Negative Results?
    Clin Infect Dis. 2025 May 15:ciaf129. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. STADLER JAM, Kuhlin JJ, Molloy SF, Mtwa NN, et al
    Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa.
    Clin Infect Dis. 2025 May 9:ciaf112. doi: 10.1093.
    PubMed     Abstract available
    
    
    
87. CHIANG SS, Campbell JR, Pelissari DM, de Oliveira MCB, et al
    The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016-2022.
    Clin Infect Dis. 2025 May 6:ciaf233. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
88. LARSSON L, Calderwood CJ, Marambire ET, Held K, et al
    Body mass index trajectories and association with tuberculosis risk in a cohort of household contacts in Southern Africa.
    Clin Infect Dis. 2025 Apr 28:ciaf222. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. DAHL VN, Pedersen OS, Butova T, Kuzhko M, et al
    Effectiveness of the BPaL(M) Regimen for Drug-Resistant Tuberculosis in Ukraine under Programmatic Conditions.
    Clin Infect Dis. 2025 Apr 25:ciaf214. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. KIM S, Pelissari DM, Harada LO, Sanchez M, et al
    Long-term mortality trends among individuals with tuberculosis: a retrospective cohort study of individuals diagnosed with tuberculosis in Brazil.
    Clin Infect Dis. 2025 Apr 18:ciaf206. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. SUTHERLAND JS, van der Spuy GD, Shaw JA, Richardson T, et al
    Performance of 2 Finger-Stick Blood Tests to Triage Adults With Symptoms of Pulmonary Tuberculosis: A Prospective Multisite Diagnostic Accuracy Study.
    Clin Infect Dis. 2025 Apr 16:ciaf105. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. MONTEPIEDRA G, Aaron L, Theron G, McCarthy K, et al
    Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics.
    Clin Infect Dis. 2025 Apr 16:ciaf198. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. 
    Correction to: Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.
    Clin Infect Dis. 2025 Apr 4:ciaf174. doi: 10.1093.
    PubMed    
    
    
    
94. STEAD D, Wasserman S, Steenkamp E, Parrish A, et al
    Comparative Performance of Urine Lipoarabinomannan and Urine Xpert MTB/RIF Ultra for Diagnosing Tuberculosis in Adult Inpatients With Human Immunodeficiency Virus in East London, South Africa.
    Clin Infect Dis. 2025 Apr 2:ciaf080. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
95. BARTL L, Zeeb M, Kalin M, Loosli T, et al
    Machine Learning-Based Prediction of Active Tuberculosis in People with HIV using Clinical Data.
    Clin Infect Dis. 2025 Mar 25:ciaf149. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. ADZEMOVIC T, Nalintya E, Fieberg A, Mande E, et al
    Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease.
    Clin Infect Dis. 2025 Mar 25:ciaf079. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. PRODANUK M, Silverberg SL, Piche-Renaud PP, Farrar DS, et al
    Adverse events of first-line therapy for pediatric tuberculosis: A systematic review and meta-analysis.
    Clin Infect Dis. 2025 Mar 24:ciaf152. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. CUELLA-MARTIN I, Hakizayezu F, Ahmed A, Runyambo D, et al
    Paucibacillary tuberculosis drives the low positive predictive value of Xpert MTB/RIF Ultra for rifampicin resistance detection in low-prevalence settings.
    Clin Infect Dis. 2025 Mar 22:ciaf132. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. MADDEN A, Ofori SK, Budu M, Sisay E, et al
    A systematic review of chronic pulmonary aspergillosis among patients treated for pulmonary tuberculosis.
    Clin Infect Dis. 2025 Mar 21:ciaf150. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. SODEKE O, Shah NS, Pals S, Riabokon S, et al
     Lower Tuberculosis Incidence Among People With Human Immunodeficiency Virus Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study.
     Clin Infect Dis. 2025 Mar 18:ciaf069. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. SINGLA R, Khan S, Silsarma A, Chavan V, et al
     Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.
     Clin Infect Dis. 2025 Mar 13:ciaf068. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2025
102. JASWAL MR, Martinez L, Brooks M, Farooq S, et al
     Tuberculosis preventive treatment for household contacts at health facility and community settings in Pakistan.
     Clin Infect Dis. 2025 Feb 27:ciaf088. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. SWARTWOOD NA, Cohen T, Marks SM, Hill AN, et al
     Effects of the COVID-19 pandemic on TB outcomes in the United States: a Bayesian analysis.
     Clin Infect Dis. 2025 Feb 27:ciaf092. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. TZELIOS CA, Malatesta S, Carney T, White LF, et al
     Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis.
     Clin Infect Dis. 2025 Feb 20:ciae642. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. SINHA A, Klebe R, Rekart ML, Alvarez JL, et al
     The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)-Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings-A Prospective Cohort Study in Belarus and Uzbekistan.
     Clin Infect Dis. 2025 Feb 18:ciaf035. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. MUNSIFF SS
     American Thoracic Society/Centers for Disease Control and Prevention/European Respiratory Society/Infectious Diseases Society of America (ATS/CDC/ERS/IDSA) Updated guideline on the treatment of tuberculosis.
     Clin Infect Dis. 2025 Feb 14:ciaf066. doi: 10.1093.
     PubMed    
     
     
     January 2025
107. MARANCHICK N, Peloquin CA, Haley CA
     Linezolid Dosing and Pharmacokinetics in North American Patients with Tuberculosis.
     Clin Infect Dis. 2025 Jan 21:ciaf027. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. ESPINOSA-PEREIRO J, Aguiar A, Nara E, Medina A, et al
     Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis.
     Clin Infect Dis. 2025 Jan 10:ciaf003. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. ARBIV OA, Holmes T, Kim MJ, Yan M, et al
     Safety of Triple-Dose Rifampin in Tuberculosis Treatment: A Systematic Review and Meta-Analysis.
     Clin Infect Dis. 2025 Jan 9:ciaf004. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2024
110. MACPHERSON L, Kik SV, Quartagno M, Lakay F, et al
     Diagnostic Accuracy of Chest X-ray Computer-Aided Detection Software for Detection of Prevalent and Incident Tuberculosis in Household Contacts.
     Clin Infect Dis. 2024 Dec 18:ciae528. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. AUMA E, Alberts R, Derendinger B, Venter R, et al
     Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility.
     Clin Infect Dis. 2024 Dec 12:ciae614. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. KHAN U, Rich M, Franke M, Lachenal N, et al
     The Frequency and Incidence of QT Prolongation with Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country MDR/RR-TB Cohort.
     Clin Infect Dis. 2024 Dec 10:ciae601. doi: 10.1093.
     PubMed     Abstract available
     
     
     
113. ZHU Y, Forsman LD, Chen C, Zhang H, et al
     Reply to He et al: Established Association Between Glycemic Control and Anti-Tuberculosis Drug Exposures After Controlling Confounding Effects.
     Clin Infect Dis. 2024 Dec 9:ciae533. doi: 10.1093.
     PubMed    
     
     
     
114. CHEN J, Xie X, Zhang A, He Y, et al
     Is There a Genuine Correlation Between Blood Glucose Control and Anti-tuberculosis Drug Concentrations, or Is it Merely an Illusion?
     Clin Infect Dis. 2024 Dec 9:ciae532. doi: 10.1093.
     PubMed    
     
     
     November 2024
115. PUYAT JH, Brode SK, Shulha H, Romanowski K, et al
     Predicting risk of tuberculosis disease in people migrating to a low-TB incidence country: development and validation of a multivariable dynamic risk prediction model using health administrative data.
     Clin Infect Dis. 2024 Nov 20:ciae561. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. ROSEN LV, Thielking AM, Dugdale CM, Montepiedra G, et al
     Tuberculosis Preventive Treatment for Pregnant People With Human Immunodeficiency Virus in South Africa: A Modeling Analysis of Clinical Benefits and Risks.
     Clin Infect Dis. 2024 Nov 15:ciae508. doi: 10.1093.
     PubMed     Abstract available
     
     
     
117. FERRAN E, Chan C, Sheikh N, Dedicoat M, et al
     Population-level frequency of fluoroquinolone resistance by whole-genome sequencing drug predictions in Mycobacterium tuberculosis complex isolates in England from 2017-2023.
     Clin Infect Dis. 2024 Nov 13:ciae560. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. PU J, Wu S, He JQ
     Efficacy and Safety of Systematic Corticosteroids treatment among HIV-Positive Patients with Tuberculosis: a systematic review and meta-analysis of randomized controlled trials.
     Clin Infect Dis. 2024 Nov 11:ciae563. doi: 10.1093.
     PubMed     Abstract available
     
     
     
119. CRITCHLEY JA, Limb ES, Khakharia A, Carey IM, et al
     Tuberculosis and increased incidence of cardiovascular disease: Cohort study using US and UK health records.
     Clin Infect Dis. 2024 Nov 4:ciae538. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2024
120. BROOKS JT, Solans BP, Beranger A, Schaaf HS, et al
     Linezolid Pharmacokinetic-Anemia Modeling in Children with Rifampicin-Resistant Tuberculosis.
     Clin Infect Dis. 2024 Oct 18:ciae497. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. NATHAVITHARANA RR, Pearl A, Biewer A, Young L, et al
     Effects of respiratory isolation for tuberculosis to reduce community-based transmission: a systematic review.
     Clin Infect Dis. 2024 Oct 14:ciae496. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. VIRDEE AK, Knudtzen FC, Llibre JM, Omland LH, et al
     Risk of tuberculosis after achieving HIV virological suppression on antiretroviral therapy: a Danish nationwide prospective cohort study.
     Clin Infect Dis. 2024 Oct 8:ciae499. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2024
123. SEIFERT M, Catanzaro DG, Gracia M, Hillery N, et al
     Prospective exploratory evaluation of Cepheid Xpert Mycobacterium tuberculosis host response cartridge: a focus on adolescents and young adults.
     Clin Infect Dis. 2024 Sep 5:ciae461. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2024
124. PADMAPRIYADARSINI C, Oswal VS, Jain CD, Mariappan MV, et al
     Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.
     Clin Infect Dis. 2024 Aug 28:ciae388. doi: 10.1093.
     PubMed     Abstract available
     
     
     
125. BOSMAN S, Ayakaka I, Muhairwe J, Kamele M, et al
     Evaluation of C-Reactive Protein and Computer-Aided Analysis of Chest X-rays as Tuberculosis Triage Tests at Health Facilities in Lesotho and South Africa.
     Clin Infect Dis. 2024 Aug 27:ciae378. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2024
126. JARRETT BA, Shearer K, Motlhaoleng K, Chon S, et al
     Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With Human Immunodeficiency Virus in the North West Province of South Africa (the Teko Study): A Cl
     Clin Infect Dis. 2024 Jul 22:ciae268. doi: 10.1093.
     PubMed     Abstract available
     
     
     
127. PRAKASH BABU S, Ezhumalai K, Raghupathy K, Karoly M, et al
     Factors associated with unfavourable treatment outcomes among persons with Pulmonary Tuberculosis: a multicentric prospective cohort study from India.
     Clin Infect Dis. 2024 Jul 11:ciae367. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. WANG MS, Li-Hunnam J, Chen YL, Gilmour B, et al
     Conversion or reversion of interferon gamma release assays for Mycobacterium tuberculosis infection: a systematic review and meta-analysis.
     Clin Infect Dis. 2024 Jul 2:ciae357. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2024
129. ZHU Y, Forsman LD, Chen C, Zhang H, et al
     Drug exposure and treatment outcomes in patients with multidrug resistant tuberculosis and diabetes mellitus: A multicenter prospective cohort study from China.
     Clin Infect Dis. 2024 Jun 24:ciae329. doi: 10.1093.
     PubMed     Abstract available
     
     
     
130. RICHTERMAN A, Saintilien E, St-Cyr M, Claudia Gracia L, et al
     Food Insecurity at Tuberculosis Treatment Initiation Is Associated With Clinical Outcomes in Rural Haiti: A Prospective Cohort Study.
     Clin Infect Dis. 2024 Jun 18:ciae252. doi: 10.1093.
     PubMed     Abstract available
     
     
     
131. RASHITOV M, Franke M, Trevisi L, Bekbolatova G, et al
     Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan.
     Clin Infect Dis. 2024 Jun 4:ciae305. doi: 10.1093.
     PubMed     Abstract available
     
     
     
132. ABBOTT R, Landsiedel K, Atukunda M, Puryear SB, et al
     Incident Tuberculosis Infection is Associated with Alcohol use in Adults in Rural Uganda.
     Clin Infect Dis. 2024 Jun 2:ciae304. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2024
133. BURKE RM, Nyirenda SK, Mtenga T, Twabi HH, et al
     Enhanced tuberculosis diagnosis with computer-aided chest X-ray and urine LAM in adults with HIV admitted to hospital (CASTLE study): A cluster randomised trial.
     Clin Infect Dis. 2024 May 15:ciae273. doi: 10.1093.
     PubMed     Abstract available
     
     
     
134. SHAH NS, Kityo C, Hughes MD, McCarthy C, et al
     Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries.
     Clin Infect Dis. 2024 May 13:ciae269. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2024
135. SINHA P, Ezhumalai K, Du X, Ponnuraja C, et al
     Undernourished Household Contacts Are at Increased Risk of Tuberculosis (TB) Disease, but not TB Infection- a Multicenter Prospective Cohort Analysis.
     Clin Infect Dis. 2024 Apr 23:ciae149. doi: 10.1093.
     PubMed     Abstract available
     
     
     
136. FARHAT MR, Jacobson KR
     For Tuberculosis, Not "To Screen or Not to Screen?" but "Who?" and "How?".
     Clin Infect Dis. 2024 Apr 18:ciae058. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. GOSWAMI N, Reed C
     Duration of Effective Tuberculosis Treatment, not Acid-Fast Bacilli (AFB) Smear Status, as the Determinant for Deisolation in Community Settings.
     Clin Infect Dis. 2024 Apr 18:ciae198. doi: 10.1093.
     PubMed    
     
     
     
138. SHAH M, Dansky Z, Nathavitharana R, Behm H, et al
     NTCA Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings.
     Clin Infect Dis. 2024 Apr 18:ciae199. doi: 10.1093.
     PubMed    
     
     
     
139. MARINER-LLICER C, Saavedra Cervera B, Mambuque E, Gomes N, et al
     Monitoring of First-line Drug Resistance Mutations Outside the Scope of Xpert MTB/RIF Ultra is Needed for Successful Control of DR-TB in Southern Mozambique.
     Clin Infect Dis. 2024;78:842-845.
     PubMed     Abstract available
     
     
     
140. MIKIASHVILI L, Kempker RR, Chakhaia TS, Bablishvili N, et al
     Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
     Clin Infect Dis. 2024;78:1043-1052.
     PubMed     Abstract available
     
     
     
141. CHABALA C, Wobudeya E, van der Zalm MM, Kapasa M, et al
     Clinical outcomes in children living with HIV treated for non-severe tuberculosis in the SHINE Trial.
     Clin Infect Dis. 2024 Apr 9:ciae193. doi: 10.1093.
     PubMed     Abstract available
     
     
     
142. RODRIGUEZ-MOLINO P, Tebruegge M, Noguera-Julian A, Neth O, et al
     Tuberculosis disease in immunocompromised children and adolescents: a pTBnet multi-centre case-control study.
     Clin Infect Dis. 2024 Apr 3:ciae158. doi: 10.1093.
     PubMed     Abstract available
     
     
     
143. PODANY AT, Cramer Y, Imperial M, Rosenkranz SL, et al
     Twice-Daily Dolutegravir Based Antiretroviral Therapy with One Month of Daily Rifapentine and Isoniazid (1HP) for TB Prevention.
     Clin Infect Dis. 2024 Apr 3:ciae183. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2024
144. BERTUMEN JB, Pascopella L, Han E, Glenn-Finer R, et al
     Epidemiology and Treatment Outcomes of Tuberculosis with Chronic Hepatitis B Infection-California, 2016-2020.
     Clin Infect Dis. 2024 Mar 26:ciae169. doi: 10.1093.
     PubMed     Abstract available
     
     
     
145. MORGAN H, Ndjeka N, Hasan T, Gegia M, et al
     Treatment of multidrug-resistant or rifampicin-resistant tuberculosis with an all-oral 9-month regimen containing linezolid or ethionamide in South Africa: A retrospective cohort study.
     Clin Infect Dis. 2024 Mar 25:ciae145. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. SUNSTRUM J, Power LE, Fligiel HM, Lauter C, et al
     Human Disease due to Mycobacterium bovis Linked to Free-Ranging Deer in Michigan.
     Clin Infect Dis. 2024;78:637-645.
     PubMed     Abstract available
     
     
     
147. KRISHNAN S, Chaisson RE
     US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.
     Clin Infect Dis. 2024;78:514-517.
     PubMed     Abstract available
     
     
     
148. NGO HX, Xu AY, Velasquez GE, Zhang N, et al
     Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
     Clin Infect Dis. 2024 Mar 11:ciae119. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2024
149. CROCKER-BUQUE T, Lachenal N, Narasimooloo C, Abdrasuliev T, et al
     Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL.
     Clin Infect Dis. 2024 Feb 29:ciad767. doi: 10.1093.
     PubMed    
     
     
     
150. TEIXEIRA LAA, Santos B, Correia MG, Valiquette C, et al
     Long-term protective effect of tuberculosis preventive therapy in a medium/high TB incidence setting.
     Clin Infect Dis. 2024 Feb 26:ciae101. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. WHITE YN, Solans BP, Denti P, van der Laan LE, et al
     Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
     Clin Infect Dis. 2024 Feb 10:ciae024. doi: 10.1093.
     PubMed     Abstract available
     
     
     
152. PIVETTA DE ARAUJO RC, Martinez L, da Silva Santos A, Ferreira Lemos E, et al
     Serial Mass Screening for Tuberculosis among Incarcerated Persons in Brazil.
     Clin Infect Dis. 2024 Feb 7:ciae055. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. STEADMAN A, Andama A, Ball A, Mukwatamundu J, et al
     New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics.
     Clin Infect Dis. 2024 Feb 2:ciae041. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2024
154. MARQUEZ C, Atukunda M, Nugent J, Charlebois ED, et al
     Community-Wide Universal Human Immunodeficiency Virus (HIV) Test and Treat Intervention Reduces Tuberculosis Transmission in Rural Uganda: A Cluster-Randomized Trial.
     Clin Infect Dis. 2024 Jan 16:ciad776. doi: 10.1093.
     PubMed     Abstract available
     
     
     
155. KU JH, Fischer H, Qian LX, Li K, et al
     Latent tuberculosis infection testing practices in a large U.S. integrated healthcare system.
     Clin Infect Dis. 2024 Jan 11:ciae015. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. GARCIA LS, Costa AG, Araujo-Pereira M, Spener-Gomes R, et al
     The Xpert(R) MTB/RIF cycle threshold value predicts M. tuberculosis transmission to close contacts in a Brazilian prospective multicenter cohort.
     Clin Infect Dis. 2024 Jan 3:ciad794. doi: 10.1093.
     PubMed     Abstract available
     
     
     
157. LINDE L, Brooks MB, Martinez L
     Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission.
     Clin Infect Dis. 2024 Jan 3:ciad791. doi: 10.1093.
     PubMed    
     
     
     December 2023
158. LIN KY, Sun HY, Yang CJ, Lu PL, et al
     Treatment responses to integrase strand-transfer inhibitor-containing antiretroviral regimens in combination with short-course rifapentine-based regimens for latent tuberculosis infection among people with HIV.
     Clin Infect Dis. 2023 Dec 5:ciad730. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2023
159. SCHWALB A, Kayumba K, Houben RMGJ, Bothamley GH, et al
     Recent travel and tuberculosis in migrants: data from a low incidence country.
     Clin Infect Dis. 2023 Nov 6:ciad672. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. LIU X, Xia L, Wang X, Huang Z, et al
     Treatment Outcomes in Multidrug-Resistant Tuberculosis During Pregnancy.
     Clin Infect Dis. 2023 Nov 1:ciad594. doi: 10.1093.
     PubMed    
     
     
     October 2023
161. BROWN TS, Tang L, Omar SV, Joseph L, et al
     Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis.
     Clin Infect Dis. 2023 Oct 24:ciad596. doi: 10.1093.
     PubMed     Abstract available
     
     
     
162. HASAN T, Medcalf E, Nyang'wa BT, Egizi E, et al
     The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis.
     Clin Infect Dis. 2023 Oct 24:ciad653. doi: 10.1093.
     PubMed     Abstract available
     
     
     
163. KHAN AR, Tirlangi PK, Wig N, Soneja M, et al
     Immortal Time Bias for Infliximab in Central Nervous System Tuberculosis.
     Clin Infect Dis. 2023 Oct 13:ciad590. doi: 10.1093.
     PubMed    
     
     
     
164. SUNG J, Nantale M, Nalutaaya A, Biche P, et al
     Evidence for tuberculosis in individuals with Xpert Ultra "trace" sputum during screening of high-burden communities.
     Clin Infect Dis. 2023 Oct 3:ciad595. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2023
165. SAUER SM, Mitnick CD, Khan U, Hewison C, et al
     Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up.
     Clin Infect Dis. 2023 Sep 29:ciad589. doi: 10.1093.
     PubMed     Abstract available
     
     
     
166. GUPTA A, Hughes MD, Cruz JL, Avihingsanon A, et al
     Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester.
     Clin Infect Dis. 2023 Sep 28:ciad583. doi: 10.1093.
     PubMed     Abstract available
     
     
     
167. KASAIE P, Pennington J, Gupta A, Dowdy DW, et al
     The impact of preventive treatment for multidrug- and rifampin-resistant tuberculosis exceeds trial-based estimates.
     Clin Infect Dis. 2023 Sep 19:ciad557. doi: 10.1093.
     PubMed     Abstract available
     
     
     
168. BOAST A, How JA, Lau C, Sett A, et al
     Pre-XDR congenital tuberculosis in an extremely premature baby.
     Clin Infect Dis. 2023 Sep 8:ciad540. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2023
169. BRUMMER LE, Thompson RR, Malhotra A, Shrestha S, et al
     Cost effectiveness of low-complexity screening tests in community-based case-finding for tuberculosis.
     Clin Infect Dis. 2023 Aug 25:ciad501. doi: 10.1093.
     PubMed     Abstract available
     
     
     
170. LOTIA FARRUKH I, Lachenal N, Adenov MM, Ahmed S, et al
     Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.
     Clin Infect Dis. 2023 Aug 22:ciad445. doi: 10.1093.
     PubMed     Abstract available
     
     
     
171. SULIMAN S, Jaganath D, DiNardo A
     Predicting Pediatric Tuberculosis: The Need for Age-Specific Host Biosignatures.
     Clin Infect Dis. 2023;77:450-452.
     PubMed    
     
     
     
172. WALLES J, Winqvist N, Hansson SR, Sturegard E, et al
     Pregnancy outcomes in women screened for tuberculosis infection in Swedish antenatal care.
     Clin Infect Dis. 2023 Aug 12:ciad465. doi: 10.1093.
     PubMed     Abstract available
     
     
     
173. BROUGH J, Martinez L, Hatherill M, Zar HJ, et al
     Public health impact and cost-effectiveness of screening for active tuberculosis disease or infection among children in South Africa.
     Clin Infect Dis. 2023 Aug 5:ciad449. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2023
174. HU Z, Liu K, Zhou M, Jiang X, et al
     Mass tuberculosis screening among the elderly: A population-based study in a well-confined rural county in eastern China.
     Clin Infect Dis. 2023 Jul 28:ciad438. doi: 10.1093.
     PubMed     Abstract available
     
     
     
175. WINGFIELD T
     Ending tuberculosis in older people: new strategies for an age-old disease.
     Clin Infect Dis. 2023 Jul 28:ciad439. doi: 10.1093.
     PubMed    
     
     
     
176. ACUNA-VILLAORDUNA C, Fennelly KP, Jones-Lopez EC
     Aerosol Sampling Outperforms Sputum to Predict Mycobacterium tuberculosis Transmission.
     Clin Infect Dis. 2023 Jul 18:ciad372. doi: 10.1093.
     PubMed    
     
     
     
177. S AM, Gautam P, D SSK, Mannam P, et al
     Effectiveness of adjunctive high dose infliximab therapy to improve disability free survival among patients with severe CNS tuberculosis: a matched retrospective cohort study.
     Clin Infect Dis. 2023 Jul 5:ciad401. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2023
178. MOON SM, Choi H, Kim SH, Kang HK, et al
     Increased lung cancer risk and associated risk factors in tuberculosis survivors: A Korean population-based study.
     Clin Infect Dis. 2023 Jun 22:ciad373. doi: 10.1093.
     PubMed     Abstract available
     
     
     
179. LUCZYNSKI P, Holmes T, Romanowski K, Arbiv OA, et al
     Risk of tuberculosis disease in people with chronic kidney disease without kidney failure: A systematic review and meta-analysis.
     Clin Infect Dis. 2023 Jun 13:ciad364. doi: 10.1093.
     PubMed     Abstract available
     
     
     
180. IWASE SC, Edlefsen PT, Bhebhe L, Motsumi K, et al
     T-SPOT.TB reactivity in Southern African children with and without in utero HIV exposure.
     Clin Infect Dis. 2023 Jun 9:ciad356. doi: 10.1093.
     PubMed     Abstract available
     
     
     
181. SOLANS BP, Imperial MZ, Olugbosi M, Savic RM, et al
     Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.
     Clin Infect Dis. 2023;76:1903-1910.
     PubMed     Abstract available
     
     
     May 2023
182. ZEEB M, Tepekule B, Kusejko K, Reiber C, et al
     Understanding the decline of incident, active tuberculosis in people with HIV in Switzerland.
     Clin Infect Dis. 2023 May 31:ciad330. doi: 10.1093.
     PubMed     Abstract available
     
     
     
183. HALEY CA, Schechter MC, Ashkin D, Peloquin CA, et al
     Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant TB disease.
     Clin Infect Dis. 2023 May 30:ciad312. doi: 10.1093.
     PubMed     Abstract available
     
     
     
184. AHSBERG J, Puplampu P, Kwashie A, Commey JO, et al
     Point-of-care urine LAM testing to guide tuberculosis treatment among severely ill in-patients with HIV in real-world practice: a multi-center stepped wedge cluster-randomized trial from Ghana.
     Clin Infect Dis. 2023 May 26:ciad316. doi: 10.1093.
     PubMed     Abstract available
     
     
     
185. KRISHNAN S, Wu X, Kim S, McIntire K, et al
     One-year incidence of tuberculosis infection and disease among household contacts of rifampin- and multi-drug resistant tuberculosis.
     Clin Infect Dis. 2023 May 25:ciad301. doi: 10.1093.
     PubMed     Abstract available
     
     
     
186. ROMANOWSKI K, Law MR, Karim ME, Campbell JR, et al
     Healthcare utilization after respiratory tuberculosis: a controlled interrupted time series analysis.
     Clin Infect Dis. 2023 May 9:ciad290. doi: 10.1093.
     PubMed     Abstract available
     
     
     
187. BOBAK CA, Botha M, Workman L, Hill JE, et al
     Gene expression in cord blood and tuberculosis in early childhood: A nested case-control study in a South African birth cohort.
     Clin Infect Dis. 2023 May 5:ciad268. doi: 10.1093.
     PubMed     Abstract available
     
     
     
188. TIMIRE C, Pedrazzoli D, Boccia D, Houben RM, et al
     Use of a sustainable livelihood framework-based measure to estimate socioeconomic impact of tuberculosis on house-holds.
     Clin Infect Dis. 2023 May 3:ciad273. doi: 10.1093.
     PubMed     Abstract available
     
     
     
189. LOUIE JK, Keh C
     Latent Tuberculosis Infection Treatment: Still a Long Road Ahead.
     Clin Infect Dis. 2023 May 1:ciad251. doi: 10.1093.
     PubMed    
     
     
     
190. MELNYCHUK L, Perlman-Arrow S, Bastos M, Menzies D, et al
     A Systematic Review and Meta-Analysis of Tuberculous Preventative Therapy Adverse Events.
     Clin Infect Dis. 2023 May 1:ciad246. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2023
191. BURKE RM, Nliwasa M, Dodd PJ, Feasey HR, et al
     Impact of community-wide tuberculosis active case finding and HIV testing on tuberculosis trends in Malawi.
     Clin Infect Dis. 2023 Apr 26:ciad238. doi: 10.1093.
     PubMed     Abstract available
     
     
     
192. CHAISSON LH
     Finding tuberculosis: More evidence for community-wide systematic screening.
     Clin Infect Dis. 2023 Apr 26:ciad232. doi: 10.1093.
     PubMed    
     
     
     
193. HUSSAIN H, Jaswal M, Farooq S, Safdar N, et al
     Scale up of rifapentine-isoniazid (3HP) for tuberculosis prevention amongst household contacts in two urban centers: An effectiveness assessment.
     Clin Infect Dis. 2023 Apr 21:ciad245. doi: 10.1093.
     PubMed     Abstract available
     
     
     
194. SABET N, Omar T, Milovanovic M, Magajane T, et al
     Undiagnosed pulmonary TB and COVID in adults dying at home in a high TB burden setting, before and during pandemic COVID-19: an autopsy study.
     Clin Infect Dis. 2023 Apr 12:ciad212. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2023
195. UPTON CM, Wiesner L, Dooley KE, Maartens G, et al
     Cerebrospinal Fluid and Tuberculosis Meningitis.
     Clin Infect Dis. 2023 Mar 29:ciad186. doi: 10.1093.
     PubMed    
     
     
     
196. ALLARD-GRAY A, Boakye I, Camara A, Eisenbeis L, et al
     Factors Associated with Discontinuation of Tuberculosis Preventive Treatment: Post-Hoc Analysis of Two Randomized Controlled Trials.
     Clin Infect Dis. 2023 Mar 23:ciad164. doi: 10.1093.
     PubMed     Abstract available
     
     
     
197. BONNET M, Gabillard D, Domoua S, Muzoora C, et al
     High performance of systematic combined urine LAM test and sputum Xpert MTB/RIF(R) for tuberculosis screening in severely immunosuppressed ambulatory adults with HIV.
     Clin Infect Dis. 2023 Mar 8:ciad125. doi: 10.1093.
     PubMed     Abstract available
     
     
     
198. LIU Q, You N, Wen J, Wang J, et al
     Yield and efficiency of a population-based mass tuberculosis screening intervention among persons with diabetes in Jiangsu Province, China.
     Clin Infect Dis. 2023 Mar 3:ciad118. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2022
199. DAVIS AG, Wasserman S, Stek C, Maxebengula M, et al
     A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis (The LASER-TBM Trial).
     Clin Infect Dis. 2022 Dec 9:ciac932. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2022
200. DAVIS AG, Dreyer AJ, Albertyn C, Maxebengula M, et al
     Cognitive Impairment in Tuberculous Meningitis.
     Clin Infect Dis. 2022 Oct 20. pii: 6763738. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum